Published in Hepatitis Weekly, May 26th, 2008
"The combination group (n = 34) received Ta1 (1.6 mg subcutaneously, twice a week) and lamivudine ( 100 mg orally, daily) for 24 weeks, followed by...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.